XML 55 R30.htm IDEA: XBRL DOCUMENT
v3.20.4

Revenue (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2020
Revenue from Contract with Customer [Abstract] |
Schedule of Disaggregation of Revenue | The following table summarizes our revenue recognized in our consolidated statements of operations:
| 2020 |  | 2019 |  | 2018
Net product revenue | $ | 22,694.8 |  |  | $ | 20,377.3 |  |  | $ | 19,866.4 |
Collaboration and other revenue(1) | 1,845.0 |  |  | 1,942.2 |  |  | 1,626.9 |
Revenue | $ | 24,539.8 |  |  | $ | 22,319.5 |  |  | $ | 21,493.3 |
(1) Collaboration and other revenue associated with prior period transfers of intellectual property was $135.6 million, $301.5 million, and $303.2 million during the years ended December 31, 2020, 2019, and 2018, respectively. The following table summarizes revenue by product:
|  |  | U.S. |  | Outside U.S.
|  |  | 2020 |  | 2019 |  | 2018 |  | 2020 |  | 2019 |  | 2018
Revenue—to unaffiliated customers: |  |  |  |  |  |  |  |  |  |  |
Diabetes: |  |  |  |  |  |  |  |  |  |  |
Trulicity® | $ | 3,835.9 |  |  | $ | 3,155.2 |  |  | $ | 2,515.8 |  |  | $ | 1,232.2 |  |  | $ | 972.7 |  |  | $ | 683.3 |
Humalog® (1) | 1,485.6 |  |  | 1,669.7 |  |  | 1,787.8 |  |  | 1,140.3 |  |  | 1,151.0 |  |  | 1,208.7 |
Humulin® | 866.4 |  |  | 879.7 |  |  | 910.2 |  |  | 393.2 |  |  | 410.4 |  |  | 421.2 |
Jardiance (2) | 620.8 |  |  | 565.9 |  |  | 400.2 |  |  | 533.0 |  |  | 378.3 |  |  | 258.1 |
Basaglar® | 842.3 |  |  | 876.2 |  |  | 622.8 |  |  | 282.1 |  |  | 236.3 |  |  | 178.5 |
Trajenta (3) | 95.6 |  |  | 224.8 |  |  | 224.2 |  |  | 263.0 |  |  | 365.8 |  |  | 350.5 |
Other Diabetes | 162.5 |  |  | 158.0 |  |  | 146.0 |  |  | 81.5 |  |  | 88.1 |  |  | 112.2 |
Total Diabetes | 7,909.1 |  |  | 7,529.5 |  |  | 6,607.0 |  |  | 3,925.3 |  |  | 3,602.6 |  |  | 3,212.5 |
Oncology: |  |  |  |  |  |  |  |  |  |  |
Alimta® | 1,265.3 |  |  | 1,219.5 |  |  | 1,131.0 |  |  | 1,064.7 |  |  | 896.4 |  |  | 1,001.9 |
Cyramza® | 381.9 |  |  | 335.3 |  |  | 291.5 |  |  | 650.8 |  |  | 589.9 |  |  | 529.9 |
Verzenio® | 618.2 |  |  | 454.8 |  |  | 248.5 |  |  | 294.4 |  |  | 124.9 |  |  | 6.6 |
Erbitux® | 480.1 |  |  | 487.9 |  |  | 531.6 |  |  | 56.3 |  |  | 55.4 |  |  | 103.8 |
Other Oncology | 46.6 |  |  | 111.0 |  |  | 200.6 |  |  | 461.0 |  |  | 339.3 |  |  | 215.1 |
Total Oncology | 2,792.1 |  |  | 2,608.5 |  |  | 2,403.2 |  |  | 2,527.2 |  |  | 2,005.9 |  |  | 1,857.3 |
Immunology: |  |  |  |  |  |  |  |  |  |  |
Taltz® | 1,288.5 |  |  | 1,016.8 |  |  | 738.7 |  |  | 500.0 |  |  | 349.6 |  |  | 198.7 |
Olumiant® | 63.8 |  |  | 42.2 |  |  | 6.7 |  |  | 575.0 |  |  | 384.7 |  |  | 195.9 |
Other Immunology | 20.0 |  |  | — |  |  | — |  |  | 14.6 |  |  | — |  |  | — |
Total Immunology | 1,372.3 |  |  | 1,059.0 |  |  | 745.4 |  |  | 1,089.6 |  |  | 734.3 |  |  | 394.6 |
Neuroscience: |  |  |  |  |  |  |  |  |  |  |
Cymbalta® | 42.1 |  |  | 49.6 |  |  | 54.3 |  |  | 725.6 |  |  | 675.8 |  |  | 653.7 |
Zyprexa® | 46.1 |  |  | 41.0 |  |  | 36.2 |  |  | 360.5 |  |  | 377.6 |  |  | 435.1 |
Emgality® | 325.9 |  |  | 154.9 |  |  | 4.9 |  |  | 37.0 |  |  | 7.7 |  |  | — |
Other Neuroscience | 73.2 |  |  | 111.0 |  |  | 182.0 |  |  | 220.9 |  |  | 305.3 |  |  | 454.5 |
Total Neuroscience | 487.3 |  |  | 356.5 |  |  | 277.4 |  |  | 1,344.0 |  |  | 1,366.4 |  |  | 1,543.3 |
Other: |  |  |  |  |  |  |  |  |  |  |
Forteo® | 510.3 |  |  | 645.5 |  |  | 757.9 |  |  | 536.0 |  |  | 759.1 |  |  | 817.7 |
Bamlanivimab (4) | 850.0 |  |  | — |  |  | — |  |  | 21.2 |  |  | — |  |  | — |
Cialis® | 61.8 |  |  | 231.7 |  |  | 1,129.2 |  |  | 545.4 |  |  | 658.8 |  |  | 722.7 |
Other | 246.4 |  |  | 291.9 |  |  | 471.8 |  |  | 321.8 |  |  | 469.7 |  |  | 553.3 |
Total Other | 1,668.4 |  |  | 1,169.1 |  |  | 2,358.8 |  |  | 1,424.4 |  |  | 1,887.7 |  |  | 2,093.7 |
Revenue | $ | 14,229.3 |  |  | $ | 12,722.6 |  |  | $ | 12,391.9 |  |  | $ | 10,310.5 |  |  | $ | 9,596.8 |  |  | $ | 9,101.4 |
Numbers may not add due to rounding. (1) Humalog revenue includes insulin lispro. (2) Jardiance revenue includes Glyxambi® and Synjardy®, and Trijardy® XR. (3) Trajenta revenue includes Jentadueto®. (4) Bamlanivimab sales are pursuant to EUA. The following table summarizes revenue by geographical area:
|  |  |  | 2020 |  | 2019 |  | 2018
Revenue—to unaffiliated customers(1): |  |  |  |  |  |
U.S. |  | $ | 14,229.3 |  |  | $ | 12,722.6 |  |  | $ | 12,391.9 |
Europe |  | 4,187.7 |  |  | 3,765.0 |  |  | 3,663.1 |
Japan |  | 2,583.1 |  |  | 2,547.6 |  |  | 2,407.4 |
China |  | 1,116.9 |  |  | 939.4 |  |  | 750.8 |
Other foreign countries |  | 2,422.7 |  |  | 2,344.9 |  |  | 2,280.1 |
Revenue |  | $ | 24,539.8 |  |  | $ | 22,319.5 |  |  | $ | 21,493.3 |
Numbers may not add due to rounding. (1) Revenue is attributed to the countries based on the location of the customer.
Schedule of Amounts Recorded for Contract Liabilities | The following table summarizes contract liability balances:
| 2020 |  | 2019
Contract liabilities | $ | 276.8 |  |  | $ | 264.6 |

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration